ASIS for Botox in Chronic Migraine

NCT02074163 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.

Interventions

DRUG: Gadolinium
DRUG: Gadolinium
DRUG: Efficacy of Botox intramuscularly at Week 6
DRUG: Efficacy of Botox intramuscularly at Week 12
DRUG: Efficacy of Botox intramuscularly at Week 18
DRUG: Efficacy of Botox intramuscularly at Week 24,
DRUG: Efficacy of Botox intramuscularly at Week 30
DRUG: Efficacy of Botox subdermally at Week 6
DRUG: Efficacy of Botox subdermally at Week 12
DRUG: Efficacy of Botox subdermally at Week 18
DRUG: Efficacy of Botox subdermally at Week 24
DRUG: Efficacy of Botox subdermally at Week 30
DRUG: Adverse Reactions of Botox intramuscularly
DRUG: Adverse Reactions of Botox subdermally

Sponsor

ASIS Corporation